Bleeding severity as an important outcome in childhood immune thrombocytopenia

Adolfo Flores, George R. Buchanan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Over the years pediatric hematologists have continued to debate whether pharmacotherapy or clinical observation should be employed as initial management in childhood immune thrombocytopenia (ITP). Delineating the fundamental elements of heterogeneity in bleeding manifestations in childhood ITP has proven to be a complicated task. Efforts to classify the impact of hemorrhage in ITP based on platelet count have been problematic. Factors beyond relying on a laboratory measurement as a surrogate marker of disease severity need to be considered. What is needed to better guide therapeutic decision-making is a clinically relevant and evidence-based measure of bleeding severity. In this special supplement, the history of therapeutic management in ITP and prior attempts to grade or quantify hemorrhage will be reviewed.

Original languageEnglish (US)
JournalPediatric Blood and Cancer
Volume60
Issue numberSUPPL.1
DOIs
StatePublished - 2013

Fingerprint

Idiopathic Thrombocytopenic Purpura
Hemorrhage
Platelet Count
Decision Making
Biomarkers
History
Observation
Pediatrics
Drug Therapy
Therapeutics

Keywords

  • Bleeding severity
  • Bleeding severity instrument
  • Childhood immune thrombocytopenia (ITP)
  • Therapeutic guidelines

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Bleeding severity as an important outcome in childhood immune thrombocytopenia. / Flores, Adolfo; Buchanan, George R.

In: Pediatric Blood and Cancer, Vol. 60, No. SUPPL.1, 2013.

Research output: Contribution to journalArticle

@article{afc33da294724758974e261e539a382e,
title = "Bleeding severity as an important outcome in childhood immune thrombocytopenia",
abstract = "Over the years pediatric hematologists have continued to debate whether pharmacotherapy or clinical observation should be employed as initial management in childhood immune thrombocytopenia (ITP). Delineating the fundamental elements of heterogeneity in bleeding manifestations in childhood ITP has proven to be a complicated task. Efforts to classify the impact of hemorrhage in ITP based on platelet count have been problematic. Factors beyond relying on a laboratory measurement as a surrogate marker of disease severity need to be considered. What is needed to better guide therapeutic decision-making is a clinically relevant and evidence-based measure of bleeding severity. In this special supplement, the history of therapeutic management in ITP and prior attempts to grade or quantify hemorrhage will be reviewed.",
keywords = "Bleeding severity, Bleeding severity instrument, Childhood immune thrombocytopenia (ITP), Therapeutic guidelines",
author = "Adolfo Flores and Buchanan, {George R.}",
year = "2013",
doi = "10.1002/pbc.24344",
language = "English (US)",
volume = "60",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "SUPPL.1",

}

TY - JOUR

T1 - Bleeding severity as an important outcome in childhood immune thrombocytopenia

AU - Flores, Adolfo

AU - Buchanan, George R.

PY - 2013

Y1 - 2013

N2 - Over the years pediatric hematologists have continued to debate whether pharmacotherapy or clinical observation should be employed as initial management in childhood immune thrombocytopenia (ITP). Delineating the fundamental elements of heterogeneity in bleeding manifestations in childhood ITP has proven to be a complicated task. Efforts to classify the impact of hemorrhage in ITP based on platelet count have been problematic. Factors beyond relying on a laboratory measurement as a surrogate marker of disease severity need to be considered. What is needed to better guide therapeutic decision-making is a clinically relevant and evidence-based measure of bleeding severity. In this special supplement, the history of therapeutic management in ITP and prior attempts to grade or quantify hemorrhage will be reviewed.

AB - Over the years pediatric hematologists have continued to debate whether pharmacotherapy or clinical observation should be employed as initial management in childhood immune thrombocytopenia (ITP). Delineating the fundamental elements of heterogeneity in bleeding manifestations in childhood ITP has proven to be a complicated task. Efforts to classify the impact of hemorrhage in ITP based on platelet count have been problematic. Factors beyond relying on a laboratory measurement as a surrogate marker of disease severity need to be considered. What is needed to better guide therapeutic decision-making is a clinically relevant and evidence-based measure of bleeding severity. In this special supplement, the history of therapeutic management in ITP and prior attempts to grade or quantify hemorrhage will be reviewed.

KW - Bleeding severity

KW - Bleeding severity instrument

KW - Childhood immune thrombocytopenia (ITP)

KW - Therapeutic guidelines

UR - http://www.scopus.com/inward/record.url?scp=84869205206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869205206&partnerID=8YFLogxK

U2 - 10.1002/pbc.24344

DO - 10.1002/pbc.24344

M3 - Article

C2 - 23109508

AN - SCOPUS:84869205206

VL - 60

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - SUPPL.1

ER -